Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952

European Journal of Cancer

Volumn 47, Issue 3, 2011, Pages 361-368

  Bouwhuis, M G ^a   Suciu, S ^b   Kruit, W ^a   Sals, F ^c   Stoitchkov, K ^d   Patel, P ^e   Cocquyt, V ^f   Thomas, J ^g   Lienard D ^h   Eggermont, A M M ^a   Ghanem, G ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d National Oncology Center Bulgaria   (Bulgaria)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adjuvant therapy; Interferon 2b; Melanoma; Prognostic marker; RCT; S100B

Indexed keywords

ALPHA2B INTERFERON; PROTEIN S100B;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE COURSE; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 79251599240     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.10.005     Document Type: Article

References (23)

1. A.J. Cochran, D.R. Wen, H.R. Herschman, and R.B. Gaynor Detection of S-100 protein as an aid to the identification of melanocytic tumors Int J Cancer 30 3 1982 295 297
2. R. Gaynor, R. Irie, D. Morton, and H.R. Herschman S100 protein is present in cultured human malignant melanomas Nature 286 5771 1980 400 401
3. A.J. Cochran, and D.R. Wen S-100 protein as a marker for melanocytic and other tumours Pathology 17 2 1985 340 345
4. R. Donato Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type Biochim Biophys Acta 1450 3 1999 191 231
5. T.A. Millward, C.W. Heizmann, B.W. Schafer, and B.A. Hemmings Calcium regulation of Ndr protein kinase mediated by S100 calcium-binding proteins EMBO J 17 20 1998 5913 5922
6. J. Markowitz, A.D. Mackerell Jr., F. Carrier, T.H. Charpentier, and D.J. Weber Design of inhibitors for S100B Curr Top Med Chem 5 12 2005 1093 1108
7. G. Ghanem, B. Loir, and R. Morandini On the release and half-life of S100B protein in the peripheral blood of melanoma patients Int J Cancer 94 4 2001 586 590
8. R. Harpio, and R. Einarsson S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma Clin Biochem 37 7 2004 512 518
9. E.D. Martenson, L.O. Hansson, and B. Nilsson Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma J Clin Oncol 19 3 2001 824 831
10. A.P. Hamberg, C.M. Korse, J.M. Bonfrer, and G.C. de Gast Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma Melanoma Res 13 1 2003 45 49
11. H. Schmidt, B.S. Sorensen, E. Nexo, and H. von der Maase S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma Melanoma Res 14 3 2004 211 215
12. L.H. Smit, C.M. Korse, and A.A. Hart Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients Eur J Cancer 41 3 2005 386 392
13. L.H. Smit, O.E. Nieweg, C.M. Korse, J.M. Bonfrer, and B.B. Kroon Significance of serum S-100B in melanoma patients before and after sentinel node biopsy J Surg Oncol 90 2 2005 66 69 discussion 9-70
14. H.B. Guo, B. Stoffel-Wagner, T. Bierwirth, J. Mezger, and D. Klingmuller Clinical significance of serum S100 in metastatic malignant melanoma Eur J Cancer 31A 11 1995 1898 1902
15. A. Hauschild, G. Engel, and W. Brenner S100B protein detection in serum is a significant prognostic factor in metastatic melanoma Oncology 56 4 1999 338 344
16. A.M. Eggermont, S. Suciu, and R. MacKie Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 9492 2005 1189 1196
17. J.D.P.R. Kalbfleisch The survival analysis of failure time data 2nd ed. 2002 Wiley New-Jersey
18. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 11 1983 710 719
19. A.A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J.M. Kirkwood Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694 J Clin Oncol 27 1 2009 38 44
20. A.M. Eggermont, S. Suciu, and M. Santinami Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 9633 2008 117 126
21. H. Gogas, J. Ioannovich, and U. Dafni Prognostic significance of autoimmunity during treatment of melanoma with interferon N Engl J Med 354 7 2006 709 718
22. M.G. Bouwhuis, S. Suciu, and S. Collette Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon J Natl Cancer Inst 101 12 2009 869 877
23. M.G. Bouwhuis, S. Suciu, and A. Testori Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991 J Clin Oncol 28 2010 2460 2466